Novavax Strikes License Deal With Pfizer for Use of Matrix-M Adjuvant

By Adriano Marchese

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments.

The biotech company said Tuesday that it has signed a nonexclusive license agreement that allows Pfizer to use Matrix-M, a vaccine ingredient that is added to stimulate immune response, in up to two disease areas with its products.

Pfizer will pay Novavax $30 million up front, with the potential of up to $500 million more if certain development and sales targets are met, Novavax said.

Novavax will also collect mid-single-digit royalties on any Pfizer products that use Matrix-M, the company said.

Write to Adriano Marchese at [e-mail]

(END) Dow Jones Newswires

01-20-26 0820ET